Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib maintenance versus placebo in primary central nervous system lymphoma in complete remission
jRCT2031230277Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary central nervous system lymphoma (PCNSL) comparing Tirabrutinib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Sep 2023; status: recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT2031230277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230277.